Recently, TGF-β was found to suppressed T helper 2-cell-mediated cancer immunity, targeting TGF-β signaling blockade in CD4+ T cells is a novel way to remodel TME and restrict tumor progression [46–48]. This evidence concerns the gene TGFB1 and neoplasm.